DeepMed Research

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis

Phase 4

Recruiting

Conditions: Multiple Sclerosis

Interventions: Drug: Ofatunumab

First Posted Date: 2024-06-05

Last Posted Date: 2025-05-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 20

Registration Number: NCT06444113

Locations: 🇺🇸
UCSF, San Francisco, California, United States
🇺🇸
UC Health Neuroscience Ctr, Aurora, Colorado, United States
🇺🇸
Northwestern Medicine Northwestern University, Winfield, Illinois, United States

and more 4 locations

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

Phase 3

Recruiting

Conditions: Sickle Cell Disease

Interventions: Biological: Crizanlizumab
Drug: Placebo

First Posted Date: 2024-06-03

Last Posted Date: 2025-05-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 315

Registration Number: NCT06439082

Locations: 🇺🇸
Childrens National Hospital, Washington, District of Columbia, United States
🇺🇸
University of Florida, Jacksonville, Florida, United States
🇺🇸
Augusta University Georgia, Augusta, Georgia, United States

and more 5 locations

A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.

Phase 4

Recruiting

Conditions: Hypercholesterolemia

Interventions: Drug: Inclisiran sodium
Drug: BPA

First Posted Date: 2024-05-29

Last Posted Date: 2025-03-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 400

Registration Number: NCT06431763

Locations: 🇩🇪
Novartis Investigative Site, Voelklingen, Germany

Prospective Observational Study to Evaluate Secukinumab Treatment Effectiveness in Pediatric Patients With Active Juvenile Enthesitis-related or Psoriatic Arthritis

Not yet recruiting

Conditions: Juvenile Idiopathic Arthritis

Interventions: Other: Secukinumab

First Posted Date: 2024-05-29

Last Posted Date: 2025-01-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 150

Registration Number: NCT06431750

Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation

Phase 4

Recruiting

Conditions: Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

Interventions: Drug: Asciminib

First Posted Date: 2024-05-24

Last Posted Date: 2025-05-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 85

Registration Number: NCT06427811

Locations: 🇮🇳
Novartis Investigative Site, Guwahati, India

Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases

Phase 1

Withdrawn

Conditions: Sjogren Disease
Systemic Lupus Erythematosus

Interventions: Drug: ianalumab

First Posted Date: 2024-05-13

Last Posted Date: 2025-01-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 12

Registration Number: NCT06411639

Home Reported Outcomes in PNH

Recruiting

Conditions: Paroxysmal Nocturnal Hemoglobinuria

Interventions: Other: PNH-relevant therapies

First Posted Date: 2024-05-13

Last Posted Date: 2025-01-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 128

Registration Number: NCT06411626

Locations: 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States

Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data

Completed

Conditions: Diffuse Large B-cell Lymphoma
Acute Lymphoblastic Leukemia (ALL)

First Posted Date: 2024-04-30

Last Posted Date: 2024-04-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 602

Registration Number: NCT06392763

Locations: 🇫🇷
Novartis, Rueil-Malmaison, France

Iptacopan in Patients With ANCA Associated Vasculitis

Phase 2

Recruiting

Conditions: Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis

Interventions: Drug: Placebo
Drug: Iptacopan
Drug: Rituximab

First Posted Date: 2024-04-29

Last Posted Date: 2025-03-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 78

Registration Number: NCT06388941

Locations: 🇺🇸
Arizona Arthritis and Rheumatology Research PLLC, Mesa, Arizona, United States
🇺🇸
Mayo Clinic Rochester, Rochester, Minnesota, United States
🇺🇸
Northwell Health, New York, New York, United States

and more 1 locations

A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

Phase 4

Active, not recruiting

Conditions: Primary Hypercholesterolemia
Mixed Dyslipidemia

Interventions: Drug: inclisiran

First Posted Date: 2024-04-26

Last Posted Date: 2025-04-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 32

Registration Number: NCT06386419

Locations: 🇮🇳
Novartis Investigative Site, Kolkata, West Bengal, India

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy